Financial analyst raises share price target for Lundbeck due to Rexulti potential
Lundbeck shares may gain added value, if the firm successfully expands the number of diseases that can be treated with its Rexulti treatment, according to financial services group.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The market is currently underestimating the underlying potential of a couple of Lundbeck's drugs, according to Norwegian financial services group DNB, which raises its share price target to DKK 305 (USD 49.3) from DKK 280 and reiterates its recommendation to buy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
